Rapport Therapeutics Inc Stock Price, News & Analysis

Rapport Therapeutics (Nasdaq: RAPP) reported new post-hoc and clinical data for RAP-219 in drug-resistant focal onset seizures presented at AES on Dec 5, 2025. The Phase 2a trial (n=30) met its primary endpoint with a statistically significant reduction in long episodes and showed a 77.8% median reduction in clinical seizures versus baseline and 24% seizure freedom during the 8-week treatment (p=0.01; seizure-free p<0.0001). RAP-219 showed early onset and consistent median efficacy across weeks 1-4 and 5-8, benefit across baseline severity groups, clinically meaningful improvements on seizure severity domains, generally favorable tolerability, and a 10% discontinuation rate. The company plans an end-of-Phase 2 FDA meeting this quarter and expects to start two pivotal Phase 3 trials in Q3 2026.

Rapport Therapeutics (Nasdaq: RAPP) will present new Phase 2a data for RAP-219 in focal onset seizures at the 2025 American Epilepsy Society Annual Meeting, Dec 5–9 in Atlanta.

Presentations include topline efficacy and safety, analyses of first-month effect, consistency of efficacy over treatment, impact of baseline disease severity, and effect on seizure severity. Posters and a Scientific Exhibit Room (GWCC B303) are scheduled for Dec 7–8; materials will be posted to the company Publications page after the conference.

Rapport Therapeutics (Nasdaq: RAPP) reported Q3 2025 results and a business update on Nov 6, 2025. Key clinical highlights include positive Phase 2a topline data for RAP-219 in drug-resistant focal onset seizures: 77.8% median reduction in clinical seizures, 72% of patients with ≥50% reduction, and 24% seizure freedom over an 8-week treatment (p-values ≤0.01). The trial met its primary electrographic endpoint (85.2% ≥30% reduction in long episodes; p<0.0001).

Corporate and financials: completed a public offering raising net proceeds of $269.4M, ended Q3 with $513.0M in cash and equivalents, and expects funding into H2 2029. Two Phase 3 trials planned to start Q3 2026; bipolar Phase 2 topline expected H1 2027.

Rapport Therapeutics (Nasdaq: RAPP) announced management will participate in two upcoming investor conferences in November 2025: a fireside chat at the Stifel 2025 Healthcare Conference in New York on Nov 13, 2025, 1:20–1:50pm ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Nov 17, 2025, 1:00–1:25pm GMT (8:00–8:25am ET).

Interested parties can access live and archived webcasts via the company’s Investors website at https://investors.rapportrx.com.

Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in an upcoming investor conference.

Management will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 11:20 am ET. The virtual event will be accessible via webcast on the company's investor relations website.

Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focusing on neurological and psychiatric disorder treatments, has announced the pricing of its public offering. The company is offering 9,615,385 shares at $26.00 per share, with an additional 30-day option for underwriters to purchase up to 1,442,307 shares.

The offering is expected to generate gross proceeds of approximately $250.0 million before deductions and is anticipated to close around September 11, 2025. Goldman Sachs, Jefferies, TD Cowen, and Stifel are serving as joint book-running managers for this offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.

Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on neurological and psychiatric disorder treatments, has announced a proposed public offering of $250.0 million of common stock. The company will grant underwriters a 30-day option to purchase up to an additional $37.5 million of shares.

The offering will be managed by joint book-runners Goldman Sachs, Jefferies, TD Cowen, and Stifel. The securities will be offered through an effective shelf registration statement previously filed with the SEC. The completion of the offering is subject to market conditions, with no guarantee of final terms or completion.

Rapport Therapeutics (NASDAQ: RAPP) announced positive topline results from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures. The trial met its primary endpoint with 85.2% of patients achieving ≥30% reduction in long episodes from baseline (p<0.0001). Notably, patients demonstrated a 77.8% median reduction in clinical seizure frequency (p=0.01), with 24% achieving complete seizure freedom during the 8-week treatment period.

The drug was generally well-tolerated, with mostly mild adverse events and no serious adverse events reported. Based on these promising results, Rapport plans to advance RAP-219 into two Phase 3 pivotal trials in Q3 2026, following an FDA end-of-Phase 2 meeting in Q4 2025. The company is also developing a long-acting injectable formulation to improve patient adherence.

Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing precision medicines for neurological and psychiatric disorders, has scheduled a conference call and webcast for September 8, 2025, at 8:00 am ET. The company will present topline results from its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.

Investors can access the call through a webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations using conference ID 4762775. A replay will be available on the company's website for 90 days after the call.